Attovia Therapeutics has successfully completed an initial public offering that raised two hundred and eighty-nine million dollars to finance its pipeline of treatments for skin disorders and inflammatory conditions. This
pharmaceuticals
14Articles
Shares of AstraZeneca fell sharply after reports confirmed that preliminary discussions regarding a potential acquisition of rival US pharmaceutical firm Bristol Myers Squibb have ceased. The UK-based company saw its
Shares of Novo Nordisk declined following weaker-than-expected sales for its oral obesity medication, while Eli Lilly continued to outperform market forecasts with its injectable treatments in the competitive weight loss
Vertex Pharmaceuticals has reported another robust earnings performance driven by its successful portfolio of treatments for cystic fibrosis, yet analysts caution that upcoming clinical data from a much smaller competitor
The United States Pharmacopeia and AAPS are set to collaborate once more for the 2026 PharmSci 360 conference, which will take place in New Orleans from October 25 to 28.
The failure of Novo Nordisk’s ziltivekimab in a pivotal clinical study has caused significant concern within the biotechnology sector, casting doubt on emerging strategies for treating cardiovascular conditions by targeting
New Sanofi chief executive Belén Garijo has stated that repairing the relationship between her company and development partner Regeneron Pharmaceuticals is now a priority objective for the pharmaceutical giant. During
Poolbeg Pharma PLC has received a Notice of Allowance from the Israeli Patent Office for its POLB 001 cancer immunotherapy-induced cytokine release syndrome patent application. The clinical-stage biopharmaceutical company is
Thalia Therapeutics plc (AIM:THAT), the AIM-listed RNA therapeutics developer, has confirmed that its proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2.75 million fundraising represent a transformational milestone for the
Jefferies has reinstated coverage of GSK PLC with a buy recommendation and a price target of 2,500 pence, representing approximately 30 per cent upside from the closing price of 1,916.50
Futura Medical shares rose after encouraging early data for a topical female sexual health gel, opening a possible new development opportunity.
The robust second quarter sales performance of Johnson and Johnson’s Spravato depression treatment has reinforced investment bank Jefferies’ view that psychedelic drug developers may be addressing a commercially viable market
Poolbeg Pharma has raised £3.5 million through a placing at 6p per share, extending its expected cash runway into the second quarter of 2028 and funding two clinical programmes.
Germany has approved higher pharmaceutical rebates, with AstraZeneca warning the measures could reduce investment, research and access to medicines.